First-Year SEC Reporting Readiness Director — Clinical Biotechnology

The mandate

The recently listed issuer has completed quarterly filings but has never run the extended annual cycle across clinical commitments, collaboration revenue, stock compensation, liquidity disclosure and emerging-company elections. Drafting ownership sits with Legal while source schedules sit in Finance and clinical teams. The first Form 10-K cannot depend on heroic reconciliation or an external adviser’s private checklist.

The engagement deliverable is a First-Year SEC Reporting Operating Model and Filing Control Book. It will map close, technical positions, disclosure inventory, drafting, tie-out, support, sub-certification, subsequent events, committee review, auditor interaction, filing authority and post-filing correction. The artefact will also define permanent roles and escalation across Finance, Legal, Clinical and Investor Relations.

Milestone one at week three produces the filing calendar, source inventory and consequence-ranked readiness gaps. Week seven closes milestone two with disclosure ownership, evidence standards and decision rights. At week twelve, milestone three delivers a full dry run using a frozen reporting date. The accepted operating model, control book, issue log and trained client team complete milestone four at week seventeen.

Acceptance requires the disclosure committee to reproduce every material annual disclosure to approved source and named judgement owner; fifteen unseen late changes must route, review and tie out correctly; and Internal Controls must reperform sampled certifications. The Controller signs after the company completes a compressed amendment and subsequent-event simulation without consultant-only workpapers.

The client will provide prior filings, trial balances, close schedules, clinical and collaboration agreements, equity records, forecasts, technical papers, disclosure controls, audit requests, legal access and a named filing team. Management retains all accounting and disclosure conclusions. Audit opinion, legal advice, investor messaging, valuation, production filing and attestation are excluded from the engagement.

Why this is external work

Management has filing knowledge but no institutional memory of an annual reporting cycle, and its advisers each see only their own workstream. External architecture supplies an independent end-to-end rehearsal and durable evidence model without preparing management’s statements, interpreting securities law or weakening auditor independence.

What you will own

• Map the annual close, accounting papers, disclosure inventory, drafting, support, tie-out, certification, committee review and filing sequence.
• Define source and judgement ownership for clinical milestones, collaborations, liquidity, equity awards, commitments and subsequent events.
• Build evidence standards linking each quantitative and narrative disclosure to approved records, calculations and accountable review.
• Exercise late trial news, revised forecast, equity modification, legal contingency, collaboration amendment and auditor adjustment scenarios.
• Establish version, comment, clearance and escalation controls across Finance, Legal, Investor Relations and external advisers.
• Design permanent capacity, role segregation, calendar buffers and decision thresholds for quarterly and annual reporting.
• Transfer the control book through a compressed dry run and client-led filing-issue retrospective before engagement closure.

Candidate qualifications

• Led SEC annual and quarterly reporting for a newly public biotechnology, pharmaceutical or complex research-stage issuer.
• Built disclosure controls joining clinical events, collaboration accounting, stock compensation, liquidity and legal review under filing deadlines.
• Directed first-year Form 10-K readiness without allowing advisers’ workpapers to become management’s undocumented control environment.
• Managed late scientific, forecast, equity and subsequent-event changes through controlled drafting, tie-out and committee approval.
• Worked with external auditors and securities counsel while preserving management responsibility and each adviser’s formal opinion boundary.
• Delivered filing operating models internal teams successfully ran after the external reporting specialists withdrew.

Non-negotiables

• The named director must lead Boston workshops and the compressed annual-filing acceptance rehearsal.
• No current relationship may involve the issuer’s auditor, filing agent or a party to a material collaboration under review.
• Management retains accounting, disclosure and filing decisions; auditors and counsel retain independent professional judgement.
• Audit opinion, legal advice, valuation, investor communications and production filing are expressly excluded.

1. 49 words maximum. Describe a first annual SEC filing where a late clinical or collaboration event changed the disclosure path.
2. 49 words maximum. How did you prove narrative disclosure completeness without relying on one executive’s memory?
3. 49 words maximum. Which client materials are essential before a compressed amendment simulation can be accepted?